Business Context and Reporting Period
This Form 8-K, dated June 1, 2021, is filed by ARYA Sciences Acquisition Corp III ("ARYA") regarding its proposed business combination with Nautilus Biotechnology, Inc. ("Nautilus"). The filing serves as a voluntary supplemental disclosure to the definitive proxy statement/prospectus to address shareholder concerns and avoid potential litigation delays. The filing also announces that the extraordinary general meeting of shareholders, scheduled for June 8, 2021, will be held remotely via teleconference due to the COVID-19 pandemic.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either ARYA or Nautilus. The document focuses on transactional terms and governance rather than operational financial performance.
- Transaction Valuation: The parties agreed on a pre-transaction equity value for Nautilus of $900 million, fixed with no adjustments.
- Transaction Fees: Placement agents Jefferies LLC and Goldman Sachs & Co. LLC are entitled to an aggregate of $5,232,500 in deferred underwriting compensation plus customary fees for the PIPE Financing and Business Combination, payable only upon successful closing.
Material Changes and Transaction Details
The filing details the negotiation timeline and specific terms agreed upon between December 2020 and February 2021:
- Negotiation Timeline: Initial non-disclosure agreement executed on December 16, 2020. Term sheet negotiations occurred between December 12 and December 14, 2020. Definitive agreements were signed on February 7, 2021.
- Board Composition: The post-closing board will consist of nine directors: six existing Nautilus directors/observers, one designated by the Sponsor, and two independent directors designated by Nautilus.
- Management Transition: No current officers of ARYA will serve as officers of the combined company. Current ARYA officers will not be employees of the combined company, and ARYA directors (except the Sponsor-designated individual) will resign upon closing.
- Incentive Plans: The combined company will implement an incentive equity plan and an employee stock purchase plan, with terms based on recommendations from an independent compensation consultant.
Guidance, Risks, and Contingencies
ARYA explicitly states that the supplemental disclosures are not an admission of legal necessity or materiality and denies the allegations in the shareholder letters. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of future events.
- Risks: Key risks include the inability to consummate the business combination, failure to obtain shareholder approval, significant redemption requests by ARYA shareholders, inability to maintain Nasdaq listing post-acquisition, and integration difficulties.
- Contingencies: Transaction fees for placement agents are conditioned solely on the successful completion of the Business Combination.
- Legal Context: The filing aims to moot disclosure claims made in four shareholder letters to prevent nuisance, cost, and distraction.
Investor Verification Checklist
- Verify the definitive proxy statement/final prospectus (Form S-4) for complete financial data and risk factors not detailed in this 8-K.
- Confirm the status of the shareholder vote scheduled for June 8, 2021, and the level of redemption requests.
- Review the specific terms of the PIPE Financing and the $900 million fixed equity valuation in the full Business Combination Agreement.
- Monitor for any updates regarding the shareholder letters or potential litigation that could delay the closing.
- Check the final composition of the post-closing board and management team once the transaction closes.